Navigating Executive Orders and DOJ Memos That Threaten Criminal Prosecution
FDA Law Blog
MAY 26, 2025
Below, we highlight some of the challenges we would see in the governments attempt to pursue these cases. Second, absent some kind of contractual relationship between a provider and a manufacturer, a provider is generally immune from misbranding if the provider is not also selling a regulated product. See 21 U.S.C.
59 
Let's personalize your content